BioNTech SE is a German multinational biotechnology company headquartered in Mainz, specializing in the development of immunotherapies and vaccines for cancer and infectious diseases. Founded in 2008 ... BioNTech SE is a German multinational biotechnology company headquartered in Mainz, specializing in the development of immunotherapies and vaccines for cancer and infectious diseases. Founded in 2008 by Uğur Şahin, Özlem Türeci, and Christoph Huber, it leverages advanced platforms like mRNA technology, next-generation immunomodulators, targeted therapies, and antibody-drug conjugates to address unmet medical needs. The company gained global prominence through its partnership with Pfizer to develop Comirnaty, the first approved mRNA-based COVID-19 vaccine, while advancing a diversified oncology pipeline with late-stage programs targeting various cancer stages, from early high-risk to metastatic diseases. BioNTech SE operates a global network of research, manufacturing, and commercial sites across Europe, North America, Asia, Australia, and Africa, including innovative BioNTainer systems for scalable mRNA production. Recent strategic moves, such as acquiring InstaDeep for AI-driven drug discovery, CureVac for enhanced mRNA capabilities, and Biotheus for advanced drug candidates, underscore its commitment to innovation. Employing over 6,000 professionals, BioNTech SE plays a pivotal role in transforming oncology and infectious disease treatments through synergistic multi-modal approaches and computational advancements.
Energy Management data not yet covered for Biontech
We have not yet reviewed Biontech's disclosures for Energy Management data.
If this data is relevant to your work, you can submit a data coverage request and our team
will investigate the company's disclosures and capture the data if available.
Account Restricted
Your account has been restricted and you no longer have access to paid features.
Contact our support team
or
upgrade your plan
to unblock your account.